Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @NedPagliarulo
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NedPagliarulo
-
Ned Pagliarulo proslijedio/la je Tweet
Biogen boosted as Mylan patent challenge fails
$BIIB$MYLhttps://www.biopharmadive.com/news/biogen-mylan-tecfidera-patent-decision/571784/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
PTAB decision on
$MYL Tecfidera challenge$BIIB +23%pic.twitter.com/QYdNBnFuv1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
An aspect of coronavirus-related disruption that I hadn't thought of:https://twitter.com/jeff_cranmer/status/1224878470666211328 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je Tweet
Dems are now chanting HR 3 — their drug pricing bill. Trump is trying to talk over them
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je Tweet
$GILD on call: No knowledge of additional#coronavirus responses to remdesivir. Waiting for clinical data. On manufacturing capacity: “We are investing heavily to be prepared as best we can.”Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je Tweet
FDA issued an Emergency Use Authorization to authorize the emergency use of CDC's 2019-Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panelhttps://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Semi regular reminder that
$GILD has ~$26 billion in cash and marketable securitiesPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Impairment charge
$GILD took on Kite assets tied to treatment of indolent NHL, whereas in 2018 it was related to a specific asset, the anti-BCMA product KTE-585:pic.twitter.com/wH5IDnagHW
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$GILD recorded impairment charge of $800M related to R&D acquired in its deal for Kite Pharma. Last Q4 it took a $820M impairment charge.http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-fourth-quarter-and-full-year-2019 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Ned Pagliarulo proslijedio/la je Tweet
The safety of the nation’s blood supply is a top FDA priority. We’ve received questions about the potential impact of the novel coronavirus (2019-nCoV) on blood safety. Respiratory viruses are generally not known to be transmitted via blood transfusion.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je Tweet
a16z's growth in biotech/healthcare investing: 2015: $200m fund + hire Vijay Ponde 2017: $450m fund + add
@JorgeCondeBio 2019: Add Julie Yoo as GP 2020: $750m fund + add@vintweeta Here's what the Bio Fund 3 team is targeting:https://www.businessinsider.com/andreessen-horowitz-750-million-bio-fund-2020-2 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HHS expanding partnership with
$REGN to develop multiple antibodies against 2019-nCoV, acc. to statement from agency this morning. No mention of funding commitment.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ned Pagliarulo proslijedio/la je Tweet
Whoa, that NEJM report from Germany claiming asymptomatic transmission of
#coronavirus turned out to be wrong The index patient did have symptoms while in Germany. German RKI has written a letter to NEJM to set the record straight https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong …https://twitter.com/AndyBiotech/status/1223068735398928385 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Instructive - and good - read on the ripple effects of drugmakers rushing in to offer up compounds with unproven efficacy in a viral outbreak:https://twitter.com/lisamjarvis/status/1224385320000638979 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Ned Pagliarulo proslijedio/la je Tweet
Everyone interested in that
#coronavirus/HIV preprint should read this debunking piece https://theprepared.com/blog/no-the-2019-ncov-genome-doesnt-actually-seem-engineered-from-hiv/ … It's unfortunate this sloppy work was widely spread and adding fuel to bioweapon conspiracy theories even though it may never pass peer-review in any serious journal...Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AIMT sets Palforzia price at $890/month or just over $10,000 a year. Right in the middle of the $3K to $20K range the company was guiding toward in run-up to approval decision.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.